Anika Therapeutics (ANIK) Accumulated Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has reported Accumulated Expenses for 17 consecutive years, with $15.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 40.68% year-over-year to $15.9 million in Q2 2026; TTM through Jun 2026 was $15.9 million, a 40.68% increase from a year earlier, with the FY2025 full-year figure at $15.9 million, up 16.95% from the prior year.
• Accumulated Expenses was $15.9 million for Q2 2026 at Anika Therapeutics, up from $14.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $19.8 million in Q3 2023 and troughed at $11.3 million in Q2 2025.
• A 5-year average of $16.1 million and a median of $15.9 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 31.53% in 2025 and surged 40.68% in 2026, its largest moves.
• Over 5 years, Accumulated Expenses stood at $18.8 million in 2022, then fell by 25.34% to $14.1 million in 2023, then dropped by 3.55% to $13.6 million in 2024, then gained by 16.95% to $15.9 million in 2025, then increased by 0.28% to $15.9 million in 2026.
• The last three Accumulated Expenses figures came in at $15.9 million (Q2 2026), $14.6 million (Q1 2026), and $15.9 million (Q4 2025), per Business Quant data.